Drug Profile
LNTH 1095
Alternative Names: 1095; 123I-MIP-1095; [131I] MIP-1095; I-131-1095; I-131-MIP-1466; I131-MIP-1095; LNTH-1095; MIP-1095; MIP-1095 I123; MIP-1095 I131; MIP-1466Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Developer Progenics Pharmaceuticals
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 25 Aug 2023 Adhoc client query: approved name updated (LNTH 1095); synonyms added (MIP 1095 I-131); DC addition request sent (radioisotopes); thes request sent to map the terms.Org role updated.
- 08 Dec 2022 LNTH 1095 is still in phase II trials for Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease) in USA and Canada (NCT03939689) (Lantheus pipeline, December 2022)
- 21 Oct 2020 Progenics Pharmaceuticals re-initiates a phase-II ARROW clinical trial in Prostate cancer (Combination therapy, Hormone refractory, Late-stage disease, Metastatic disease) in USA and Canada (PO) (NCT03939689)